摘要
目的 :通过建立焦虑大鼠模型,研究中药复方滋肾疏肝胶囊的抗焦虑作用及其机制。方法 :采用不确定性空瓶刺激法制备焦虑大鼠模型,24只大鼠随机分为4组,即空白对照组、模型组、地西泮片给药组、滋肾疏肝胶囊给药组,除空白对照组外,分别以蒸馏水、地西泮片、滋肾疏肝胶囊灌胃给药。运用RT-PCR和Western Blotting方法分别检测5-羟色胺1A受体(5-HT1AR)m RNA及蛋白表达水平,单因素方差分析相关数据。结果:与空白对照组比较,模型组大鼠攻击行为和修饰行为频率均显著性升高(P<0.01),高架十字迷宫实验OE%和OT%值均显著性下降(P<0.01),海马区5-HT1AR m RNA及蛋白表达均显著性降低(P<0.01)。与模型组比较,滋肾疏肝胶囊给药组大鼠攻击行为和修饰行为频率均显著性降低(P<0.01),OE%和OT%值均显著性升高(P<0.01),海马区5-HT1AR m RNA及蛋白表达均显著性升高(P<0.01)。结论:滋肾疏肝胶囊对焦虑症大鼠具有明显的治疗效果,5-HT1AR基因可能是该药物的作用靶点。
Objective:To study the antianxiety effect and its mechanism of Zishen Shugan capsule by establishing anxiety rat model. Methods:The anxiety rat model was established by uncertainty stimulation of empty bottle. The 24 rats were randomly divicled into 4 groups:control group,model group,diazepam tablet group and Zishen Shugan capsule group. Except the control group,other groups were given distilled water,diazepam tablet and Zishen Shugan capsule by gavage respectively. The expressions of m RNA and protein of 5-hydroxy tryptamine 1A receptor(5-HT1AR) were respectively detected by RT-PCR and Western blotting.The data was analyzed by One-factor analysis of variance. Results:Compared with control group,the frequency of both aggressive behavior and grooming behavior of model group increased significantly(P 〈0.01),the open arm entry percent(OE%) and the open arm time percent(OT%) of elevated plus-maze test de creased significantly(P 〈0.01),the m RNA and protein expressions of 5-HT1 AR in the hippocampus decreased significantly(P 〈0.01). Compared with model group,the frequency of both aggressive behavior and grooming behavior of Zishen Shugan capsule group decreased significantly(P 〈0.01),the OE% and OT% increased significantly(P 〈0.01),the m RNA and protein expressions of 5-HT1 AR increased significantly(P 〈0.01). Conclu sion:Zishen Shugan capsule had significant curative effect on anxiety rat and the gene 5-HT1 AR could be the drug target.
出处
《山东中医药大学学报》
2015年第2期154-157,共4页
Journal of Shandong University of Traditional Chinese Medicine
基金
山东省中医药科技发展计划项目(编号:2013-035)